


Claims

1. A compound of Formula (VI):



or a pharmaceutically acceptable salt thereof, wherein:

R^{2A} and R^{2B} are independently H, OH or C₁-C₄ alkyl, provided at least one of R^{2A} and R^{2B} is not H;

R³ is C₁-C₄ fluoroalkyl;


R⁴ is H;

R^{5A} is SO₂R⁷ or SO₂NR⁸R⁹;


R⁷ is C₁-C₄ alkyl; and

R⁸ and R⁹ are independently H or C₁-C₄ alkyl.


2. A compound or a pharmaceutically acceptable salt thereof according to claim 1 which is of Formula (VI-A):



3. A compound or a pharmaceutically acceptable salt thereof according to claim 2 which is of Formula (VI-B):



5 4. A compound or a pharmaceutically acceptable salt thereof according to claim 2 which is of Formula (VI-C):



5. A compound or a pharmaceutically acceptable salt thereof according to any one
10 of claims 1 to 4, wherein R³ is C₁-C₂ fluoroalkyl.

6. A compound or a pharmaceutically acceptable salt thereof according to claim 5, wherein R³ is CF₂H or CH₂CF₂H.

7. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein R⁷ is CH₃.

8. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R⁸ and R⁹ are independently H or CH₃.

9. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein:

one of R^{2A} and R^{2B} is OH and the other is CH₃; or

one of R^{2A} and R^{2B} is OH and the other is H; or

one of R^{2A} and R^{2B} is H and the other is CH₃;

R³ is CF₂H or CH₂CF₂H;

R⁴ is H;

R^{5A} is SO₂R⁷; and

R⁷ is CH₃.

10. A compound or a pharmaceutically acceptable salt thereof according to claim 1 which is:

(+)-6-(2,2-difluoroethyl)-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)piperidin-4-yl]amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

(-)-6-(2,2-difluoroethyl)-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)piperidin-4-yl]amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-(difluoromethyl)-8-[(1*R*,2*R*)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)piperidin-4-yl]amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

(-)-4-({6-(difluoromethyl)-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-7-oxo-7,8-dihydropyrido[2,3-*d*]pyrimidin-2-yl}amino)-*N*-methylpiperidine-1-sulfonamide;

(+)-4-({6-(difluoromethyl)-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-7-oxo-7,8-dihydropyrido[2,3-*d*]pyrimidin-2-yl}amino)-*N*-methylpiperidine-1-sulfonamide;

8-[(1*R*,2*R*)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)piperidin-4-yl]amino]-6-(trifluoromethyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;


6-(difluoromethyl)-8-[(1*S*,2*S*)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)piperidin-4-yl]amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

(-)-4-({6-(difluoromethyl)-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-7-oxo-7,8-dihydropyrido[2,3-*d*]pyrimidin-2-yl}amino)piperidine-1-sulfonamide; or

(+)-4-({6-(difluoromethyl)-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-7-oxo-7,8-dihydropyrido[2,3-*d*]pyrimidin-2-yl}amino)piperidine-1-sulfonamide.

11. A compound or a pharmaceutically acceptable salt thereof according to any one of claim 1 to 3, which is 6-(difluoromethyl)-8-[(1*R*,2*R*)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-*d*]pyrimidin-7(8*H*)-one.

5 12. A compound according to claim 11 which is:



13. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, and a pharmaceutically acceptable carrier or excipient.

10 14. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 for use as a medicament.

15. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 for use in the treatment of abnormal cell growth.

15 16. A compound for use according to claim 15 wherein said abnormal cell growth is cancer.

17. A compound for use according to claim 16, wherein the cancer is (a) breast cancer or ovarian cancer; (b) characterized by amplification or overexpression of cyclin E1 (CCNE1) and cyclin E2 (CCNE2); or (c) both (a) and (b).

20 18. A compound for use according to any one of claims 15 to 17 wherein said compound is to be administered sequentially or simultaneously with at least one additional pharmaceutical or medicinal agent.

19. A compound for use according to claim 18 wherein said additional pharmaceutical or medicinal agent is an anti-cancer agent.

25 20. A compound for use according to claim 18 wherein said additional pharmaceutical or medicinal agent is tamoxifen, docetaxel, paclitaxel, cisplatin,

capecitabine, gemcitabine, vinorelbine, exemestane, letrozole, fulvestrant, anastrozole or trastuzumab.